52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA FROM INTERIM ANALYSIS OF PHASE 2 VIVACITY-MG STUDY OF NIPOCALIMAB (M281) IN GENERALIZED MYASTHENIA GRAVIS (GMG)
* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS
* MOMENTA PHARMACEUTICALS INC - DOES NOT INTEND TO PAUSE ENROLLMENT OF PHASE 2 CLINICAL STUDY OF NIPOCALIMAB
Japanese automaker Toyota Motor Corp has partnered with Chinese autonomous driving startup Momenta to develop a high definition (HD) mapping platform in China for autonomous driving vehicles, Momenta said in a statement.
Amphastar Pharmaceuticals Inc on Wednesday said Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.
* AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ
A federal appeals court on Thursday dismissed as moot a challenge by Momenta Pharmaceuticals Inc to a Bristol-Myers Squibb Inc patent for treating immune system disorders, saying Momenta had no legally protected interest in the patent.
A federal judge on Monday ruled that Amphastar Pharmaceuticals Inc must wait to collect a $100 million bond that Momenta Pharmaceuticals Inc and Sandoz Inc posted in a drug patent case it won until after an appellate court hears the dispute.
* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML
* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME FOR CONTRACTED GLATOPA (GLATIRAMER ACETATE INJECTION) FILL/FINISH MANUFACTURER Source text for Eikon: Further company coverage:
* MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING Source text:(http://bit.ly/2CTkx5R) Further company coverage:
* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS
Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.
* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)
* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update
* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)
* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update
* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.